These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 6114495)

  • 1. Effect of lergotrile mesylate and methysergide on morphine induced increase in prolactin release.
    Ratner A; Woo W; Yelvington D; Torres K
    Proc West Pharmacol Soc; 1981; 24():335-9. PubMed ID: 6114495
    [No Abstract]   [Full Text] [Related]  

  • 2. Lergotrile mesylate: an in vivo dopamine agonist which blocks dopamine receptors in vitro.
    Kebabian JW; Calne DB; Kebabian PR
    Commun Psychopharmacol; 1977; 1(4):311-8. PubMed ID: 615694
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibition of prolactin secretion by lergotrile mesylate: mechanism of action.
    Clemens JA; Smalstig EB; Shaar CJ
    Acta Endocrinol (Copenh); 1975 Jun; 79(2):230-7. PubMed ID: 166535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morphine can stimulate prolactin release independent of a dopaminergic mechanism.
    Shin SH; Obonsawin MC; Van Vugt DA; Baby N; Jhamandas K
    Can J Physiol Pharmacol; 1988 Nov; 66(11):1381-5. PubMed ID: 2907416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interaction of dopaminergic and serotonergic drugs on plasma prolactin in ovariectomized, estrogen-treated rats.
    Lawson DM; Gala RR
    Endocrinology; 1976 Jan; 98(1):42-7. PubMed ID: 1248448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methysergide and metergoline reduce morphine analgesia with no effect on the development of tolerance in rats.
    Romandini S; Samanin R
    Psychopharmacology (Berl); 1984; 82(1-2):140-2. PubMed ID: 6420824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulatory effect of the dopa-decarboxylase inhibitor Ro 4-4602 on prolactin release; inhibition by l-dopa, metergoline, methysergide and 2-Br-alpha-ergocryptine.
    Pontiroli AE; Castegnaro E; Vettaro MP; Viberti GC; Pozza G
    Acta Endocrinol (Copenh); 1977 Jan; 84(1):36-44. PubMed ID: 318788
    [No Abstract]   [Full Text] [Related]  

  • 8. Possible involvement of dopamine in the release of prolactin-like hormone from bullfrog pituitary gland.
    Kikuyama S; Seki T
    Gen Comp Endocrinol; 1980 Jun; 41(2):173-9. PubMed ID: 6968286
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of methysergide and pimozide on apomorphine-induced growth hormone secretion in men.
    Lal S; Guyda H; Bikadoroff S
    J Clin Endocrinol Metab; 1977 Apr; 44(4):766-70. PubMed ID: 849986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of the effects of lisuride and pimozide on the preovulatory surge of FSH, LH and prolactin in rat.
    Kun I; Simionescu L; Oprescu M; Zamfir-Grigorescu D
    Endocrinologie; 1984; 22(3):177-82. PubMed ID: 6436960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential enhancement of locomotor activity by dopamine agonists following chronic morphine treatment.
    Tye NC; Horsman L; Wright FC; Pullar IA
    Psychopharmacology (Berl); 1979 May; 63(3):313-5. PubMed ID: 39310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of prolactin secretion by a direct effect of methysergide on the pituitary lactotrophs in the rat.
    Krulich L; Coppings RJ; McCann SM; Mayfield MA
    Life Sci; 1978 Oct; 23(16):1665-73. PubMed ID: 723442
    [No Abstract]   [Full Text] [Related]  

  • 13. Dopamine agonist-induced hyperglycemia in rats: effects of lergotrile mesylate.
    Schmidt MJ
    Eur J Pharmacol; 1979 Oct; 59(1-2):95-101. PubMed ID: 41730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of the dopamine agonist, lergotrile mesylate, on prolactin secretion in women.
    Leebaw W; Lee L; Woolf P
    Acta Endocrinol (Copenh); 1978 Jan; 87(1):12-8. PubMed ID: 579527
    [No Abstract]   [Full Text] [Related]  

  • 15. Stereotyped responses of rats to two 2-halogenoergolines: 2-bromo-alpha-ergocryptine and lergotrile.
    Bergmann F
    Isr J Med Sci; 1982 Jan; 18(1):177-82. PubMed ID: 6121772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine agonistic potency of two novel prolactin release-inhibiting ergolines.
    Markó M
    Eur J Pharmacol; 1984 Jun; 101(3-4):263-6. PubMed ID: 6468500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A chronically hypoprolactinemic rat model: administration of lergotrile mesylate by osmotic minipump.
    Mills DE; Buckman MT; Peake GT
    Proc Soc Exp Biol Med; 1981 Mar; 166(3):438-41. PubMed ID: 6111081
    [No Abstract]   [Full Text] [Related]  

  • 18. Studies on the antiparkinsonism efficacy of lergotrile.
    Lieberman A; Miyamoto T; Battista AF; Goldstein M
    Neurology; 1975 May; 25(5):459-62. PubMed ID: 166332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopaminergic mediation of beta-endorphin-induced prolactin secretion.
    Van Loon GR; De Souza EB; Shin SH
    Neuroendocrinology; 1980 Oct; 31(4):293-6. PubMed ID: 6252497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism of lergotrile to 13-hydroxy lergotrile, a potent inhibitor of prolactin release in vitro.
    Parli CJ; Schmidt B; Shaar CJ
    Biochem Pharmacol; 1978 May; 27(9):1405-8. PubMed ID: 29651
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.